Acadia Pharmaceuticals (ACAD) Cost of Revenue (2016 - 2026)

Acadia Pharmaceuticals has reported Cost of Revenue for 11 years, with the latest figure at $24.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 21.57% year-over-year to $24.8 million; the trailing twelve-month figure through Mar 2026 stood at $93.4 million (up 17.8% YoY), and the FY2025 full-year result was $89.0 million, up 8.75% from the prior year.
• Cost of Revenue for Q1 2026 stood at $24.8 million, down from $26.2 million in the prior quarter.
• The five-year high for Cost of Revenue was $26.2 million in Q4 2025, with the low at $1.7 million in Q1 2023.
• Average Cost of Revenue over 5 years is $14.6 million, with a median of $18.2 million recorded in 2024.
• Year-over-year, Cost of Revenue tumbled 77.54% in 2022 and jumped 1276.78% in 2024.
• Tracing ACAD's Cost of Revenue over 5 years: stood at $2.4 million in 2022, then surged by 641.44% to $17.9 million in 2023, then grew by 21.87% to $21.8 million in 2024, then climbed by 20.28% to $26.2 million in 2025, then fell by 5.47% to $24.8 million in 2026.
• The last three Cost of Revenue figures came in at $24.8 million (Q1 2026), $26.2 million (Q4 2025), and $21.6 million (Q3 2025), per Business Quant data.

Peer Comparison